Pipeline
Guarding tumor crossroads: we are developing precision therapies targeting multiple high value oncogenic pathways.
AML is the most commonly diagnosed adult leukemia with an estimated 23,000 newly diagnosed cases in the United States each year. About 30% AML cases are driven by mutations in FLT3. Most patients who receive either Quizartinib (front line therapy) or Gilteritinib (Relapsed Refractory) as treatment, eventually have disease progression either due to the emergence of other FLT3 mutations or escape mechanisms. The multitude of FLT3 clones requires constant pan-FLT3 inhibition to avoid resistant mutations while simultaneously inhibiting escape mechanisms.
We develop the best-in-class highly efficacious and selective pan-variant FLT3 and IRAK4 inhibitor that addresses the limitations of current therapies by targeting clinically relevant FLT3 mutations and escape mechanisms at the same time.
| PROGRAM/TARGET | INDICATION | DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|---|---|
| lomonitinib FLT3/IRAK4 |
AML | |||||
| lonitoclax BCL2 | CLL | |||||
| AML | ||||||
| balomenib Menin |
AML | |||||
| PTPN2 INHIBITOR 
|
IO/SOLID TUMORS | |||||
| JAK2V617F INHIBITOR |
Polycythemia Vera/Myelofibrosis | |||||
| MALT1 DEGRADER |
B-cell lymphomas, I&I | |||||
| BTK COVALENT AND REVERSIBLE INHIBITOR | B-cell lymphomas, I&I | |||||
| Selective Brain Penetrant CDK2 INHIBITOR |
SOLID TUMORS | |||||
| Selective Brain Penetrant CDK4 INHIBITOR |
SOLID TUMORS | |||||
| Orally Bioavailable KRASG12D INHIBITOR |
SOLID TUMORS | |||||
| Brain & lung penetrable reversible pan-EGFR INHIBITOR |
SOLID TUMORS | |||||
| pan-KRAS Molecular Glue |
SOLID TUMORS | |||||
| c-MET | SOLID TUMORS | |||||
| PROGRAM/TARGET |
PTPN2 INHIBITOR
|
|---|---|
| INDICATION | IO/SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | JAK2V617F INHIBITOR |
|---|---|
| INDICATION | Polycythemia Vera/Myelofibrosis |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | MALT1 DEGRADER |
|---|---|
| INDICATION | B-cell lymphomas, I&I |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | BTK COVALENT AND REVERSIBLE INHIBITOR |
|---|---|
| INDICATION | B-cell lymphomas, I&I |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | Selective Brain Penetrant CDK2 INHIBITOR |
|---|---|
| INDICATION | SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | Selective Brain Penetrant CDK4 INHIBITOR |
|---|---|
| INDICATION | SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | Orally Bioavailable KRASG12D INHIBITOR |
|---|---|
| INDICATION | SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | Brain & lung penetrable reversible panEGFR INHIBITOR |
|---|---|
| INDICATION | SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | panKRAS Molecular Glue |
|---|---|
| INDICATION | SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | c-MET |
|---|---|
| INDICATION | SOLID TUMORS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|